Hims & Hers Health, Inc.

Средний индекс, значительно упал. Оптимистичный взгляд на свои позиции резко сменился на неуверенность.

Medium index, significantly down. An optimistic view of his position suddenly changed to uncertainty.

Сильный индекс, незначительно упал. Рынок не поддерживает быков.

Strong index, slightly down. The market does not support the bulls.

Средний индекс, значительно упал. Отток средств из лонгов резко увеличился и находится на высоком уровне.

Medium index, significantly down. The outflow of funds from longs has increased sharply and is at a high level.

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in SoFi Technologies Inc (Symbol: SOFI), where a total volume of 684,445 contracts has been traded thus far today, a contract volume which is representative of approximately 68.4 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 83.3% of SOFI's average daily trading volume over the past month, of 82.1 million shares. Especially high volume was seen for the $15.50 strike call option expiring July 31, 2026, with 35,451 contracts trading so far today, representing approximately 3.5 million underlying shares of SOFI. Below is a chart showing SOFI's trailing twelve month trading history, with the $15.50 strike highlighted in orange:
Hims & Hers Health Inc (Symbol: HIMS) saw options trading volume of 114,547 contracts, representing approximately 11.5 million underlying shares or approximately 78.7% of HIMS's average daily trading volume over the past month, of 14.6 million shares. Especially high volume was seen for the $25 strike put option expiring July 31, 2026, with 5,327 contracts trading so far today, representing approximately 532,700 underlying shares of HIMS. Below is a chart showing HIMS's trailing twelve month trading history, with the $25 strike highlighted in orange:
And EchoStar Corp (Symbol: ECHO) options are showing a volume of 37,238 contracts thus far today. That number of contracts represents approximately 3.7 million underlying shares, working out to a sizeable 71.1% of ECHO's average daily trading volume over the past month, of 5.2 million shares. Especially high volume was seen for the $75 strike put option expiring August 21, 2026, with 6,542 contracts trading so far today, representing approximately 654,200 underlying shares of ECHO. Below is a chart showing ECHO's trailing twelve month trading history, with the $75 strike highlighted in orange:
For the various different available expirations for SOFI options, HIMS options, or ECHO options, visit StockOptionsChannel.com.
Further SOFI Research:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Noteworthy Wednesday Option Activity: SOFI, HIMS, ECHO

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in IMAX Corp. (Symbol: IMAX), where a total volume of 6,295 contracts has been traded thus far today, a contract volume which is representative of approximately 629,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 60.4% of IMAX's average daily trading volume over the past month, of 1.0 million shares. Particularly high volume was seen for the $44 strike call option expiring December 18, 2026, with 5,002 contracts trading so far today, representing approximately 500,200 underlying shares of IMAX. Below is a chart showing IMAX's trailing twelve month trading history, with the $44 strike highlighted in orange:
GE Vernova Inc (Symbol: GEV) options are showing a volume of 18,074 contracts thus far today. That number of contracts represents approximately 1.8 million underlying shares, working out to a sizeable 60.2% of GEV's average daily trading volume over the past month, of 3.0 million shares. Particularly high volume was seen for the $1460 strike call option expiring August 21, 2026, with 387 contracts trading so far today, representing approximately 38,700 underlying shares of GEV. Below is a chart showing GEV's trailing twelve month trading history, with the $1460 strike highlighted in orange:
And Hims & Hers Health Inc (Symbol: HIMS) saw options trading volume of 94,043 contracts, representing approximately 9.4 million underlying shares or approximately 59.1% of HIMS's average daily trading volume over the past month, of 15.9 million shares. Particularly high volume was seen for the $33.50 strike call option expiring July 17, 2026, with 8,389 contracts trading so far today, representing approximately 838,900 underlying shares of HIMS. Below is a chart showing HIMS's trailing twelve month trading history, with the $33.50 strike highlighted in orange:
For the various different available expirations for IMAX options, GEV options, or HIMS options, visit StockOptionsChannel.com.
Further IMAX Research:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Noteworthy Friday Option Activity: IMAX, GEV, HIMS

In the latest trading session, Hims & Hers Health, Inc. (HIMS) closed at $22.04, marking a +1.94% move from the previous day. The stock exceeded the S&P 500, which registered a gain of 0.27% for the day. Elsewhere, the Dow saw a downswing of 0.31%, while the tech-heavy Nasdaq appreciated by 0.88%.
Heading into today, shares of the company had gained 67.73% over the past month, outpacing the Medical sector's gain of 2.89% and the S&P 500's gain of 2.85% in that time.
The upcoming earnings release of Hims & Hers Health, Inc. will be of great interest to investors. The company is expected to report EPS of $0.05, up 266.67% from the prior-year quarter. Simultaneously, our latest consensus estimate expects the revenue to be $295.32 million, showing a 42.04% escalation compared to the year-ago quarter.
HIMS's full-year Zacks Consensus Estimates are calling for earnings of $0.18 per share and revenue of $1.23 billion. These results would represent year-over-year changes of +263.64% and +40.58%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Hims & Hers Health, Inc. These revisions help to show the ever-changing nature of near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. At present, Hims & Hers Health, Inc. boasts a Zacks Rank of #1 (Strong Buy).
From a valuation perspective, Hims & Hers Health, Inc. is currently exchanging hands at a Forward P/E ratio of 120.47. Its industry sports an average Forward P/E of 22.43, so one might conclude that Hims & Hers Health, Inc. is trading at a premium comparatively.
The Medical Info Systems industry is part of the Medical sector. With its current Zacks Industry Rank of 69, this industry ranks in the top 28% of all industries, numbering over 250.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow HIMS in the coming trading sessions, be sure to utilize Zacks.com.
Where Will Stocks Go…
If Biden Wins? If Trump Wins?
The answers may surprise you.
Since 1950, even after negative midterm years, the market has never had a lower presidential election year. With voters energized and engaged, the market has been almost unrelentingly bullish no matter which party wins!
Now is the time to download Zacks' free Special Report with 5 stocks that offer extreme upside for both Democrats and Republicans…
1. Medical manufacturer has gained +11,000% in the last 15 years.
2. Rental company is absolutely crushing its sector.
3. Energy powerhouse plans to grow its already large dividend by 25%.
4. Aerospace and defense standout just landed a potentially $80 billion contract.
5. Giant Chipmaker is building huge plants in the U.S.
Hurry, Download Special Report FREE >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Hims & Hers Health, Inc. (HIMS) Outpaces Stock Market Gains: What You Should Know

Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Principal US Small-Cap ETF (Symbol: PSC) where we have detected an approximate $419.9 million dollar inflow -- that's a 18.3% increase week over week in outstanding units (from 33,600,001 to 39,740,001). Among the largest underlying components of PSC, in trading today Sezzle Inc (Symbol: SEZL) is down about 7.9%, Hims & Hers Health Inc (Symbol: HIMS) is up about 0.2%, and Credo Technology Group Holding Ltd (Symbol: CRDO) is lower by about 2.7%. For a complete list of holdings, visit the PSC Holdings page » The chart below shows the one year price performance of PSC, versus its 200 day moving average:
Looking at the chart above, PSC's low point in its 52 week range is $51.34 per share, with $70.5638 as the 52 week high point — that compares with a last trade of $68.23. Comparing the most recent share price to the 200 day moving average can also be a useful technical analysis technique -- learn more about the 200 day moving average ».
Exchange traded funds (ETFs) trade just like stocks, but instead of ''shares'' investors are actually buying and selling ''units''. These ''units'' can be traded back and forth just like stocks, but can also be created or destroyed to accommodate investor demand. Each week we monitor the week-over-week change in shares outstanding data, to keep a lookout for those ETFs experiencing notable inflows (many new units created) or outflows (many old units destroyed). Creation of new units will mean the underlying holdings of the ETF need to be purchased, while destruction of units involves selling underlying holdings, so large flows can also impact the individual components held within ETFs.
Further PSC Research:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Principal US Small-Cap ETF Experiences Big Inflow

Key Points
Hims & Hers Health continues to drive impressive growth through its subscription-based consumer wellness platform.
Teladoc Health maintains a dominant market share with over 100 million global members and significant institutional partnerships.
Which digital healthcare stock is the better choice for your portfolio in 2026?
As virtual care evolves, choosing between Hims & Hers Health (NYSE:HIMS) and Teladoc Health (NYSE:TDOC) depends on whether you prefer explosive growth in consumer subscriptions or established, large-scale institutional healthcare partnerships.
Hims & Hers focuses on direct-to-consumer wellness solutions for specific conditions, such as hair loss and weight management. Teladoc provides a comprehensive virtual care platform for employers and health plans. While both lead in digital health, their paths to profitability and market strategies represent very different investment opportunities for 2026.
The case for Hims & Hers Health
Hims & Hers operates a direct-to-consumer digital health platform within the broader healthcare stocks category. It provides personalized treatment plans for hair care, mental health, and weight loss, serving nearly 2.6 million subscribers as of Q1 2026. The company is currently scaling its operations through the pending acquisition of Eucalyptus and recently secured a $400 million receivables facility with JPMorgan Chase (NYSE:JPM) to support its pharmacy operations.
In FY 2025, the company reported revenue of nearly $2.3 billion, representing approximately 59.0% growth from the previous fiscal year. It achieved net income of approximately $128.4 million during this period, a slight increase from the prior year. This resulted in a net margin, or the percentage of revenue remaining after all expenses, of roughly 5.5%.
As of its December 2025 balance sheet, the debt-to-equity ratio is approximately 2.1x. This ratio measures a company's total debt against the value of its ownership interest. The current ratio, which measures the ability to cover short-term liabilities with short-term assets, stands at nearly 1.9x.
The case for Teladoc Health
Teladoc serves over 100 million members globally through its Integrated Care and BetterHelp segments. It recently expanded its distribution through a strategic partnership with Walmart (NASDAQ:WMT) to integrate virtual care into retail platforms. However, the company remains dependent on a limited number of large clients, with its top five customers historically accounting for nearly 19% of total revenue.
During FY 2025, Teladoc reported revenue of approximately $2.5 billion, which was a slight decrease of nearly 1.5% from the prior year. The company recorded a net loss of close to $200.3 million for the fiscal year, though this narrowed significantly from the $1.0 billion net loss recorded in the year prior. This performance led to a negative net margin of roughly 7.9% as the company continues to work toward consistent profitability.
According to the December 2025 balance sheet, the debt-to-equity ratio is approximately 0.8x. The current ratio is nearly 2.7x, indicating a strong ability to meet immediate financial obligations.
Risk profile comparison
Hims & Hers Health faces significant regulatory pressure regarding compounded GLP-1s and peptides, with the FDA indicating potential restrictions on certain ingredients. The company is also navigating a potential investigation by the DOJ and HHS regarding its business practices. Furthermore, the rapid integration of acquisitions such as Eucalyptus poses operational risks that could undermine the company's ability to maintain its growth trajectory.
Teladoc Health deals with heavy customer concentration, where the loss of a major health plan client could materially damage its financials. The BetterHelp segment has struggled with declining paying users, adding pressure to the company's overall growth. Teladoc also faces intense competition from established giants like Amazon (NASDAQ:AMZN) and Alphabet, (NASDAQ:GOOG) (NASDAQ:GOOGL) which are increasingly entering the virtual care market with their own digital health initiatives.
Valuation comparison
Teladoc Health offers a lower P/S ratio, while Hims & Hers Health carries a higher forward P/E due to its rapid growth.
Forward P/E
78.9x
59.4x
389.1x
P/S ratio
3.5x
0.7x
Sector benchmark uses the SPDR XLV sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.
Which stock would I buy in 2026?
Consumers have more choices than ever when it comes to healthcare providers, like Hims & Hers and Teladoc. The companies provide different services, but it’s useful to compare them because they represent two different strategies that appeal to investors with different goals.
Like many consumer wellness platforms, Hims & Hers targets personal health needs, particularly those that are repetitive in nature and lend themselves to subscription services, such as sexual health and weight loss. Compounded GLP-1 medications have been an especially lucrative offering for the company. Hims & Hers trades at a premium valuation, which may worry investors due to potential regulatory issues and increasing market competition.
Teladoc provides virtual healthcare visits, connecting patients to a network of medical professionals. The company makes money from employers and healthcare plans that pay subscription fees. Virtual doctor visits skyrocketed during the pandemic, but as clinics and physicians’ practices reopened, the stock plunged. But most of Teladoc’s troubles stem from its acquisition of Livongo and expenses related to its BetterHelp brand. The good news is its very low valuation and turnaround strategy, which is starting to pay off.
Investors who are willing to invest in bargain stocks with the hope of a big future payoff may find Teladoc’s stock compelling. But Hims & Hers remains a steady growth engine, generating predictable revenue from its direct-to-consumer subscription services. For this reason, I’d choose Hims & Hers.
Should you buy stock in Hims & Hers Health right now?
Before you buy stock in Hims & Hers Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $418,761!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,195,804!*
Now, it’s worth noting Stock Advisor’s total average return is 918% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of July 6, 2026.
JPMorgan Chase is an advertising partner of Motley Fool Money. Pamela Kock has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Alphabet, Amazon, Hims & Hers Health, JPMorgan Chase, Teladoc Health, and Walmart. The Motley Fool has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Hims & Hers Health vs. Teladoc Health: Which Healthcare Stock Is a Better Buy in 2026?

Hims & Hers Health, Inc. (HIMS) closed at $33.39 in the latest trading session, marking a -1.62% move from the prior day. The stock's change was less than the S&P 500's daily gain of 1.18%. Meanwhile, the Dow experienced a rise of 0.59%, and the technology-dominated Nasdaq saw an increase of 2.07%.
The company's stock has climbed by 29.79% in the past month, exceeding the Medical sector's gain of 7.96% and the S&P 500's loss of 2.9%.
Analysts and investors alike will be keeping a close eye on the performance of Hims & Hers Health, Inc. in its upcoming earnings disclosure. The company is expected to report EPS of -$0.06, down 135.29% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $689.49 million, up 26.55% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.23 per share and a revenue of $2.9 billion, indicating changes of -143.4% and +23.72%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Hims & Hers Health, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, ranging from #1 (Strong Buy) to #5 (Strong Sell), possesses a remarkable history of outdoing, externally audited, with #1 stocks returning an average annual gain of +25% since 1988. The Zacks Consensus EPS estimate remained stagnant within the past month. Hims & Hers Health, Inc. is currently a Zacks Rank #5 (Strong Sell).
In terms of valuation, Hims & Hers Health, Inc. is presently being traded at a Forward P/E ratio of 646.48. This denotes a premium relative to the industry average Forward P/E of 27.78.
It's also important to note that HIMS currently trades at a PEG ratio of 48.52. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Medical Info Systems was holding an average PEG ratio of 2.09 at yesterday's closing price.
The Medical Info Systems industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 110, placing it within the top 46% of over 250 industries.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions.
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Hims & Hers Health, Inc. (HIMS) Stock Falls Amid Market Uptick: What Investors Need to Know

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Hims & Hers Health Inc (Symbol: HIMS), where a total volume of 150,425 contracts has been traded thus far today, a contract volume which is representative of approximately 15.0 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 79.6% of HIMS's average daily trading volume over the past month, of 18.9 million shares. Particularly high volume was seen for the $35 strike call option expiring June 26, 2026, with 15,835 contracts trading so far today, representing approximately 1.6 million underlying shares of HIMS. Below is a chart showing HIMS's trailing twelve month trading history, with the $35 strike highlighted in orange:
Restaurant Brands International Inc (Symbol: QSR) options are showing a volume of 27,631 contracts thus far today. That number of contracts represents approximately 2.8 million underlying shares, working out to a sizeable 76.2% of QSR's average daily trading volume over the past month, of 3.6 million shares. Especially high volume was seen for the $75 strike call option expiring July 17, 2026, with 16,523 contracts trading so far today, representing approximately 1.7 million underlying shares of QSR. Below is a chart showing QSR's trailing twelve month trading history, with the $75 strike highlighted in orange:
And Capricor Therapeutics Inc (Symbol: CAPR) options are showing a volume of 7,668 contracts thus far today. That number of contracts represents approximately 766,800 underlying shares, working out to a sizeable 75.2% of CAPR's average daily trading volume over the past month, of 1.0 million shares. Especially high volume was seen for the $20 strike put option expiring August 21, 2026, with 5,735 contracts trading so far today, representing approximately 573,500 underlying shares of CAPR. Below is a chart showing CAPR's trailing twelve month trading history, with the $20 strike highlighted in orange:
For the various different available expirations for HIMS options, QSR options, or CAPR options, visit StockOptionsChannel.com.
Further HIMS Research:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Friday Option Activity: HIMS, QSR, CAPR

(RTTNews) - Today's top gainers include Regentis, amid developments including its withdrawal of a planned U.S. listing application (Form F-1) with the SEC; Cuprina, following FDA clearance for its maggot debridement therapy; and Intellia, after reporting additional positive results for its hereditary angioedema program, among others.
Read on…
Regentis Sprints Higher
Regentis Biomaterials Ltd. (RGNT) led the pack of gainers on Monday, with shares zooming over 500%, following a strategic decision to withdraw its Form F 1 registration statement filed with the SEC.
The company had filed the Form F-1 with the SEC on May 1, 2026, proposing a firm commitment offering of 3.33 million ordinary shares at an assumed price of $3.00 per share (based on its NYSE American closing price on April 28, 2026).
Regentis Biomaterials' lead asset is GelrinC, an off-the-shelf regenerative cartilage repair product. The product is approved with the CE Mark in Europe. As part of preparations for the commercial rollout of GelrinC, the company plans to begin European surgeon training activities in the third quarter of 2026.
In the U.S., GelrinC is in a pivotal study that has recruited and treated 47 of the required 80 initial patients. Recruitment in the study is expected to be completed in the third quarter of this year.
RGNT closed Monday's trading at $9.40, up 526.67%.
CUPR Gets FDA Clearance for Maggot Debridement Therapy
Cuprina Holdings (Cayman) Ltd. (CUPR) received FDA clearance for MEDIFLY Maggots, its medical-grade Lucilia cuprina larvae used in maggot debridement therapy on Monday, sending shares up over 100%.
The product is cleared for the debridement of non-healing necrotic skin and soft tissue wounds, including pressure ulcers, neuropathic foot ulcers, and non-healing traumatic or post-surgical wounds.
The company already holds U.S. FDA commercial rights to another maggot species Lucilia sericata, licensed from Dr. Ronald A. Sherman, a pioneer of modern maggot debridement therapy (MDT) and Cuprina's Medical and Scientific Director.
Lucilia sericata-derived Medical Maggots became the first medicinal maggot product to receive FDA clearance in 2004.
CUPR closed Monday's trading at $8.41, up 111.84%.
NTLA On Track To Meet Targets
Intellia Therapeutics Inc. (NTLA) jumped more than 20% on Monday, following additional positive phase 3 results for Lonvoguran Ziclumeran (lonvo-z) in patients with hereditary angioedema.
A rolling biologics license application (BLA) submission for lonvo-z was initiated this April with the FDA, and the company is targeting regulatory approval and a U.S. launch in the first half of 2027.
NTLA closed Monday's trading at $14.92, up 23.20%.
MYO on the Move
Myomo Inc. (MYO), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, jumped 17% on Monday on no specific news.
While reporting its first-quarter results last month, the company projected second-quarter 2026 revenue of $10.3 million to $10.8 million and reaffirmed its full-year 2026 revenue guidance of $43 million to $46 million. This compares with revenue of $9.7 million in the second quarter of 2025 and $40.9 million for the full year 2025.
MYO closed Monday's trading at $1.35, up 17.39%.
HIMS Gets Its Edge Back
Shares of Hims & Hers Health Inc. (HIMS), a health and wellness platform, were up over 12% on Monday.
HIMS, which took a hit in February this year after becoming embroiled in a patent dispute with Novo Nordisk over semaglutide, appears to be getting its mojo back, now that the legal battle has been resolved.
Last month, the company introduced generic semaglutide through its platform in Canada, which marks its first international generic GLP-1 offering.
HIMS closed Monday's trading at $30.17, up 12.49%.
TXG Catches the Market's Eye
10x Genomics Inc. (TXG), a genomics tools company, gained more than 11% on Monday despite the absence of any company-specific news.
In the first quarter of 2026, the company recorded a narrower loss even as revenue slipped 3% over the comparable year-ago quarter.
For full-year 2026, the company expects revenue of $600 million to $625 million, representing flat to 4% growth over full-year 2025.
TXG closed Monday's trading at 432.22, up 11.72%.
Did you know?
Hyposmia, which refers to loss of smell, is a common early sign of Parkinson's disease and can appear years or even decades before diagnosis. (Source: Parkinson's Foundation).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Top Biotech Gainers: RGNT Withdraws F-1 Filing, FDA Clears CUPR's Maggot Therapy, MYO On Watch

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Sezzle Inc (Symbol: SEZL), where a total volume of 3,987 contracts has been traded thus far today, a contract volume which is representative of approximately 398,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 73.1% of SEZL's average daily trading volume over the past month, of 545,405 shares. Particularly high volume was seen for the $135 strike call option expiring January 15, 2027, with 1,005 contracts trading so far today, representing approximately 100,500 underlying shares of SEZL. Below is a chart showing SEZL's trailing twelve month trading history, with the $135 strike highlighted in orange:
Hims & Hers Health Inc (Symbol: HIMS) saw options trading volume of 133,255 contracts, representing approximately 13.3 million underlying shares or approximately 70.1% of HIMS's average daily trading volume over the past month, of 19.0 million shares. Especially high volume was seen for the $28 strike call option expiring June 12, 2026, with 14,624 contracts trading so far today, representing approximately 1.5 million underlying shares of HIMS. Below is a chart showing HIMS's trailing twelve month trading history, with the $28 strike highlighted in orange:
And Royal Caribbean Group (Symbol: RCL) saw options trading volume of 19,124 contracts, representing approximately 1.9 million underlying shares or approximately 63.2% of RCL's average daily trading volume over the past month, of 3.0 million shares. Particularly high volume was seen for the $250 strike put option expiring September 18, 2026, with 6,848 contracts trading so far today, representing approximately 684,800 underlying shares of RCL. Below is a chart showing RCL's trailing twelve month trading history, with the $250 strike highlighted in orange:
For the various different available expirations for SEZL options, HIMS options, or RCL options, visit StockOptionsChannel.com.
Further SEZL Research:
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Notable Friday Option Activity: SEZL, HIMS, RCL

Hims & Hers Health (NYSE: HIMS) is trying to turn GLP-1 demand, subscriber growth, and international expansion into a much larger healthcare platform. The stock has dropped sharply, margins are under pressure, and valuation still looks demanding, but the long-term upside could become more compelling if Hims proves it can cross-sell into higher-margin care categories.
Stock prices used were the market prices of May 28, 2026. The video was published on June 4, 2026.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
Should you buy stock in Hims & Hers Health right now?
Before you buy stock in Hims & Hers Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $439,847!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,342,065!*
Now, it’s worth noting Stock Advisor’s total average return is 968% — a market-crushing outperformance compared to 211% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
*Stock Advisor returns as of June 5, 2026.
Rick Orford has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool has a disclosure policy. Rick Orford is an affiliate of The Motley Fool and may be compensated for promoting its services. If you choose to subscribe through their link, they will earn some extra money that supports their channel. Their opinions remain their own and are unaffected by The Motley Fool.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Indicator	TTM Median
P/E	27.40 21.49
Price/Sales	3.49 3.03
P/B	14.43 2.57
P/FCF	105.38 18.61

Indicator	TTM Median
ROE	0.00 19.43
ROA	7.21 6.99
ROI	0.00 9.91
Net Worth	7.92 0.21
Quick Ratio	1.56 1.79
Current Ratio	1.69 2.79

Indicator	TTM Median
Net Profit Margin	0.00 11.32
Operating Margin	4.51 14.11
Gross Margin	73.81 75.26
Return on tangible equity	0.00 44.85

Indicator	TTM Median
EPS	0.07 0.43
EPS Forecast	0.02 0.37
Revenue	608.00M 17.00M
Gross Profit	397.00M —
EBITDA	28.00M —

Hims & Hers Health, Inc.

Recent quarterly and TTM performance

Valuation

Debts

Efficiency

Other ratios

Revenue